What question did this study set out to answer?

The aim is to assess different experimental biofilm models for their pharmacokinetic and pharmacodynamic properties.

Experimental biofilm models for pharmacokinetic and pharmacodynamic investigations: bridging in vitro , ex vivo and in vivo systems

View Full Paper

Ask AI

Bookmark

Authors

Review outlines models linking pharmacokinetics and pharmacodynamics in biofilm research, suggesting improved outcomes for antimicrobial therapies.

The aim is to assess different experimental biofilm models for their pharmacokinetic and pharmacodynamic properties.
Evaluated various biofilm models including in vitro, ex vivo, and in vivo systems.
Analyzed strengths and limitations of each model type.
Discussed metrics like minimum biofilm inhibitory concentration (MBIC) and minimum biofilm eradication concentration (MBEC).
In vitro models allow high-throughput screening of antimicrobial compounds.
Ex vivo models maintain host architecture to study topical therapies.
In vivo systems are crucial for understanding host-pathogen interactions and their systemic effects.

Supparitsch et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Review outlines models linking pharmacokinetics and pharmacodynamics in biofilm research, suggesting improved outcomes for antimicrobial therapies.